编辑专栏文章 - 后台系统

编辑专栏文章

编辑专栏文章

文章标题：

标　　签：

关键字：

药品词链接：

插入此药品介绍区块

文章分类：

文章主图*

点击“Select image”更换图片

Select image Change Remove

注意! 最佳图片尺寸200*200

将主图插入到内容

内容详情：

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="font-family:微软雅黑"><span style="font-weight:normal"><font face="微软雅黑">阿帕替尼是抗血管生产药物，联合小分子靶向药物卡博替尼的</font></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">对</font>RET原癌基因突变的晚期肺腺癌患者的治疗效果</span></span></span></span></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">，</font></span></span></span></span></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">医院研究结果如下：</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"> </p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"> </p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">本例患者最初接受了培美曲塞联合顺铂的方案化疗</font>4个周期后疾病进展,PFS为94 d;调整治疗方案为多西他赛单药化疗4个周期并联合低剂量阿帕替尼(250 mg·d</span></span></span></span></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">-1</font></span></span></span></span></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">)抗血管生成治疗后,患者疾病部分缓解,PFS为88 d;疾病再次进展后改用卡博替尼单药(60 mg·d</font></span></span></span></span></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">-1</font></span></span></span></span></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">)靶向治疗2周后无效,PFS为0 d,但联合低剂量阿帕替尼(250 mg·d</font></span></span></span></span></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">-1</font></span></span></span></span></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">)抗血管生成后,患者胸水较前显著吸收,PS评分较前改善,疾病部分缓解,PFS为46 d。</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"> </p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"> </p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">结论:本例RET突变的晚期肺腺癌患者对化疗有效,对卡博替尼单药靶向治疗无效,但对低剂量的阿帕替尼(250 mg·d</font></span></span></span></span></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">-1</font></span></span></span></span></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">)联合卡博替尼反应良好。</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><img alt="" src="../upload/61bae381e9ca3193605084.png" style="width: 299px; height: 360px;" /></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"> </p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><a href="http://www.jingrenjiankang.com/p/drug_detail.php?navid=6&id=41"><span style="color:#2980b9;"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑"><strong>卡博替尼</strong></font></span></span></span></span></a><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">虽然在国内还没有正式上市，但是在临床上的研究越来越多了，应用范围越来越广泛。目前仿制版的卡博替尼有孟加拉和老挝的，价格在</font>2000-4000之间。如果您有关于靶向药卡博替尼方面的疑问，可直接致电鲸人健康顾问热线：</span></span></span></span></span></span></span><b><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="font-weight:bold"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">18515676770/15321833786（微信同号）</font></span></span></span></span></span></span></span></span></b></span></span></p>

首页显示：

显示不显示

热门文章：

是否

阅读：

定时发送：

否是